Best-known as the world's largest diabetes company, it made sense that Novo Nordisk A/S would increase its research efforts in the cardiovascular space, building on its learnings over the past decade.
Novo Nordisk Committed To Advancing In Cardiovascular
As Ziltivekimab Shows Promise
The Danish major’s head of development tells Scrip that as cardiovascular disease is very closely related to obesity and diabetes, Novo Nordisk has the expertise to thrive in the former.
More from Cardiovascular
More from Therapy Areas
• By
The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.
• By
Following the near-total dominance of IgG antibodies, the UK group is backing the potential of IgA and IgE-based therapies to transform cancer treatment with the purchase of US-headquartered TigaTx.
• By
By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.